Halyard Health (NYSE:HYH) was upgraded by equities researchers at TheStreet from a “c+” rating to a “b” rating in a research note issued on Monday.

A number of other brokerages have also recently weighed in on HYH. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. Stifel Nicolaus reissued a “buy” rating and issued a $52.00 price objective on shares of Halyard Health in a research report on Friday, November 3rd. Zacks Investment Research lowered Halyard Health from a “buy” rating to a “sell” rating in a research report on Wednesday, October 4th. KeyCorp reissued a “hold” rating on shares of Halyard Health in a research report on Tuesday, October 17th. Finally, BidaskClub raised Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $44.00.

Shares of Halyard Health (NYSE HYH) traded up $0.26 during trading on Monday, reaching $47.67. The company had a trading volume of 214,638 shares, compared to its average volume of 346,681. Halyard Health has a 52-week low of $35.24 and a 52-week high of $50.99. The firm has a market capitalization of $2,253.77, a PE ratio of 23.02, a P/E/G ratio of 2.60 and a beta of 1.77. The company has a quick ratio of 1.19, a current ratio of 2.13 and a debt-to-equity ratio of 0.49.

Halyard Health (NYSE:HYH) last issued its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.13. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The firm had revenue of $401.40 million for the quarter, compared to analysts’ expectations of $394.54 million. During the same quarter last year, the firm earned $0.48 earnings per share. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. analysts predict that Halyard Health will post 2.08 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC purchased a new position in Halyard Health in the first quarter valued at about $727,000. Koch Industries Inc. purchased a new position in Halyard Health in the second quarter valued at about $297,000. TIAA CREF Investment Management LLC raised its position in Halyard Health by 35.2% in the second quarter. TIAA CREF Investment Management LLC now owns 202,901 shares of the medical instruments supplier’s stock valued at $7,970,000 after purchasing an additional 52,881 shares during the period. Prudential Financial Inc. raised its position in Halyard Health by 3.9% in the third quarter. Prudential Financial Inc. now owns 686,309 shares of the medical instruments supplier’s stock valued at $30,904,000 after purchasing an additional 25,680 shares during the period. Finally, Schwab Charles Investment Management Inc. raised its position in Halyard Health by 3.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 797,993 shares of the medical instruments supplier’s stock valued at $31,346,000 after purchasing an additional 27,421 shares during the period. 90.31% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/06/halyard-health-hyh-raised-to-b-at-thestreet.html.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.